Short answer
Celcuity Inc. (CELC) filed its Q3 2025 10-Q quarterly report on Nov 13, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$44M
- −47.0% YoY · +3.2% QoQ
- EPS (diluted)
- −$0.91
- −30.0% YoY · +12.5% QoQ
Source: XBRL data from the Celcuity Inc. (CELC) Q3 2025 10-Q on SEC EDGAR. USD.
Celcuity Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: increased tariffs and trade policy uncertainty due to U.S. changes triggering retaliatory foreign actions and exemptions increasing cost volatility
- Most updated regulatory risk: FDA leadership loss and funding cuts raising timing and approval uncertainties for drug applications and clinical guidance
- Legal risk: $331.3M total indebtedness limits cash flow and could trigger defaults if covenants breached, affecting operations and refinancing capacity
- Operational risk: reliance on gedatolisib API supply affected by tariffs, raising material costs and operational execution risks amid global trade tensions
- Financial risk: $220M additional term loans available contingent on milestones, increasing leverage and contingent future debt obligations impacting liquidity
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Celcuity Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.